FDA Scrutiny Looms For Unapproved Research Tests

By Jeff Overley (November 25, 2013, 8:45 PM EST) -- The U.S. Food and Drug Administration on Monday edged away from controversial plans to force manufacturers of unapproved diagnostic tests sold for research purposes to ensure that their customers don't use the products for commercial purposes, but there's still plenty of reason to believe that stronger enforcement is on the horizon, experts say.

In finalized guidance, the FDA deleted a provision saying it "may consider a manufacturer's knowledge of the purposes for which its customers offer and use its [in vitro diagnostic] product" when deciding whether a company had tacitly endorsed commercial use of tests that lacked approval but could still...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!